Tivic Health appoints Veronica Cai as CFO, Ryan Sabia as COO; CFO Benz resigns

Valion Bio, Inc.

Briana Benz resigned as CFO effective April 1, 2022; 93,750 restricted shares repurchased for $375.
Veronica Cai appointed CFO with $325k base salary, 25% bonus target, and options for 117,880 shares at $1.61.
Ryan Sabia (COO since Dec 2021) enters employment agreement with $250k base salary and 25% bonus target.
Sanjay Ahuja joins as SVP Quality Assurance & Regulatory Affairs (press release).
Benz's departure not due to any disagreement with the company's operations or policies.

item 1.01 item 5.02 item 1.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Veronica Cai

Chief Financial Officer

VBIO · Valion Bio, Inc.

Effective: 2022-04-01
Filed: April 5, 2022, 7:59 PM ET

On April 1, 2022, Veronica Cai was appointed as the Company’s new Chief Financial Officer.

Departed

Briana Benz

Chief Financial Officer

VBIO · Valion Bio, Inc.

Effective: 2022-04-01
Successor: Veronica Cai
Filed: April 5, 2022, 7:59 PM ET

On April 1, 2022, Briana Benz resigned from her role as Chief Financial Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Veronica Cai was appointed as Chief Financial Officer at Valion Bio, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On April 1, 2022, Veronica Cai was appointed as the Company’s new Chief Financial Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Briana Benz resigned as Chief Financial Officer at Valion Bio, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On April 1, 2022, Briana Benz resigned from her role as Chief Financial Officer of Tivic Health Systems, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.

View on SEC.gov

Valion Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-042811

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.